UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dupilumab: A review of its use in the treatment of atopic dermatitis

Journal of the American Academy of Dermatology, 2018-03, Vol.78 (3), p.S28-S36

2018

Volltextzugriff (PDF)

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

The New England journal of medicine, 2021-12, Vol.385 (24), p.2219-2229

2021

Volltextzugriff (PDF)

Clinical Evaluation of a Microwave Device for Treating Axillary Hyperhidrosis

Dermatologic surgery, 2012-05, Vol.38 (5), p.728-735

2012

Volltextzugriff (PDF)

A Comprehensive Approach to the Recognition, Diagnosis, and Severity‐Based Treatment of Focal Hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee

Dermatologic surgery, 2007-08, Vol.33 (8), p.908-923

2007

Volltextzugriff (PDF)

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2151-2168

2021

Volltextzugriff (PDF)

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2020-03, Vol.145 (3), p.877-884

2020

Volltextzugriff (PDF)

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2324833

2024

Volltextzugriff (PDF)

Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey

Journal of cutaneous medicine and surgery, 2024-07, Vol.28 (4), p.387-388

2024

Volltextzugriff (PDF)

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

The Lancet (British edition), 2022-07, Vol.400 (10348), p.273-282

2022

Volltextzugriff (PDF)

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Dermatologic therapy, 2024-05, Vol.14 (5), p.1145-1160

2024

Volltextzugriff (PDF)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2287-2303

2017

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

JAMA dermatology (Chicago, Ill.), 2022-04, Vol.158 (4), p.404

2022

Volltextzugriff (PDF)

Erythema multiforme major associated with SARS-CoV-2 infection in a patient with skin of colour

Canadian Medical Association journal (CMAJ), 2023-11, Vol.195 (46), p.E1581-E1582

2023

Volltextzugriff (PDF)

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis

Dermatology and therapy, 2023-10, Vol.13 (10), p.2247-2264

2023

Volltextzugriff (PDF)

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Dermatology and therapy, 2024-02, Vol.14 (2), p.441-451

2024

Volltextzugriff (PDF)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2023-06, Vol.159 (6), p.596

2023

Volltextzugriff (PDF)

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Frontiers in medicine, 2021-09, Vol.8, p.682547-682547

2021

Volltextzugriff (PDF)

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Journal of allergy and clinical immunology, 2023-01, Vol.151 (1), p.172-181

2023

Volltextzugriff (PDF)

Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective

Journal of the American Academy of Dermatology, 2023-08, Vol.89 (2), p.372-375

2023

Volltextzugriff (PDF)

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

The Journal of dermatological treatment, 2020-02, Vol.31 (2), p.152-159

2020

Volltextzugriff (PDF)

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British journal of dermatology (1951), 2023-10, Vol.189 (5), p.540-552

2023

Volltextzugriff (PDF)

Considerations for defining and diagnosing generalized pustular psoriasis

Journal of the European Academy of Dermatology and Venereology, 2024-09

2024

Volltextzugriff (PDF)

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

Journal of the American Academy of Dermatology, 2024-08, Vol.91 (2), p.273-280

2024

Volltextzugriff (PDF)

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

British journal of dermatology (1951), 2023-05, Vol.188 (6), p.810-812

2023

Volltextzugriff (PDF)

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis

Dermatology and therapy, 2022-05, Vol.12 (5), p.1181-1196

2022

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(98)
Bücher
(1)

Sprache

Englisch
(98)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Dupilumab: A review of its use in the treatment of atopic dermatitis

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

Clinical Evaluation of a Microwave Device for Treating Axillary Hyperhidrosis

A Comprehensive Approach to the Recognition, Diagnosis, and Severity‐Based Treatment of Focal Hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

Erythema multiforme major associated with SARS-CoV-2 infection in a patient with skin of colour

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

Considerations for defining and diagnosing generalized pustular psoriasis

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis

Suchergebnisse filtern